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Tumor-regressions following tumor-associated-antigen vaccination in animal models contrast with the limited clinical
outcomes in cancer patients. Most animal studies however used subcutaneous-tumor-models and questions arise as
whether these are relevant for tumors growing in mucosae; whether specific mucosal-homing instructions are required;
and how this may be influenced by the tumor.
Persistent infection by oncogenic types
of human papillomavirus (HPV) is the
central etiological agent of several ano-
genital cancers, including cervical cancer,
the second cause of cancer death in
women worldwide. Since carcinogenesis
requires stable expression of HPV-E6
and -E7 oncogenes, these have been
tumor-associated-antigens of choice for
immunotherapeutic strategies. Parenterally
administered therapeutic vaccines have
been under active development during
the past twenty years. However, none has
shown enough clinical efficacies to reach
commercialization. To address the role of
immunization routes for inducing tumor-
protection in mucosal locations (Fig. 1),
we developed a novel orthotopic murine
model for cervical cancer.1 We compared
parenteral and mucosal immunization
routes for their ability to induce E7-
specific cytotoxic T lymphocytes (E7-
CTL) in the genital mucosa (GM), as
well as protection against genital tumors
(GT). Our data showed that subcutane-
ous (s.c.) immunization with an adju-
vanted E7 polypeptide was more efficient
than intranasal (i.n.) or intravaginal (ivag)
routes at inducing systemic responses.
The three immunization routes induced
however similar numbers of E7-CTL in
the GM, suggesting a better homing of
these lymphocytes to the GM after i.n.
and ivag immunization.2 This is in line
with the concept of a common mucosal
immune system, where antigen presenta-
tion occurring in a mucosal site lead to
priming of lymphocytes with a tendency
to selectively home to the same or other
specific mucosal sites. How far this
concept can be applied to the GM has
been a matter of controversy with either
parenteral or different mucosal immun-
ization routes yielding disparate results
with different vaccines and/or readouts.3,4
Superiority or efficacy of mucosal lym-
phocyte trafficking has however been only
assessed for the induction of immune
responses after infections and/or immun-
ization or to provide protection against a
pathogenic challenge. Whether this may
hold true for inducing regression of
mucosal tumor was to our knowledge
not previously examined.
Knowing that our adjuvanted s.c. E7
vaccine provides regression of s.c. tumors
through E7-CTL,5 we anticipated that the
induction of an almost identical frequency
and high-avidity of E7-CTL in the GM by
either of the immunization routes would
predict a similar ability to induce protec-
tion in the GM. Indeed our data showed
that either i.n. or s.c. immunization were
able to fully prevent GT implantation.
However, and surprisingly, only s.c.
immunization was able to efficiently
induce regression of already established
E7-expressing GT, the most notable
difference of s.c. immunization being the
higher number of systemic and circulating
E7-CTL induced, as compared with i.n.
immunization. Clearly the growing tumors
must influence the vaccine-induced
immune response. In absence of vaccina-
tion, the growing GT induce local E7-
CTL (up to 20% of the CD8+ T cells),
which are however counteracted by an
important infiltration of CD4+ Foxp3+ T
regulatory cells (Treg, up to 60% of the
CD4+ T cells).1 Interestingly, GT regres-
sing upon vaccination showed up to 90%
E7-CTL among the infiltrating CD8+
T cells, together with a decrease in Treg
(less than 15% of the infiltrating CD4+
T cells, unpublished data), both prob-
ably accounting for the vaccine efficacy.
Although we have no clue as how
vaccination led to a decrease in infiltrated
Treg, our data suggest that the higher
number of circulating E7-CTL present
after s.c. immunization, as compared with
i.n. immunization, may readily infiltrate
the tumor thus explaining higher efficacy
of this immunization route even in the
case of a mucosal site. Lymphocyte
trafficking to the GM has involved both
mucosal and non-mucosal homing inter-
actions especially upon infections.6,7 In
contrast, the growing tumors induce little
innate immunity and the intratumoral
vasculature appears to rather limit lympho-
cyte recruitment by decreasing or altering
adhesion molecule expression.8,9 It is thus
the interplay between vaccination and the
tumor that may lead to such an efficient
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CTL infiltration in the regressing tumor.
Interestingly, systemic administration of
CpG-oligonucleotides (which are used in
our case as adjuvant to the E7 vaccine)
was found to induce ICAM-1 and
VCAM- 1 on intratumoral vessels, thus
enabling strong T cell infiltrations in a
pancreatic islet tumor murine model.10
Whether this also occurs in our setting
when the E7-vaccine is administered by
the s.c. route, but not the i.n. route,
deserve further investigation. This inter-
play between tumor location and vaccina-
tion routes is probably even more
complex, as tumors implanted s.c. did
regress after both i.n. and s.c. immuniza-
tion.2 To gain additional insights, we are
examining how the same vaccine may
induce regression of tumors located in
another, nearby, mucosal site i.e., the
bladder. Interestingly, our preliminary
data suggest that homing to the bladder
follow different rules than homing to
the GM, with both s.c. and ivag immun-
ization routes, but not i.n., leading to
similar frequencies of E7-CTL in bladder.
More surprisingly however, ivag immun-
ization was more efficient to induce
regression of tumors established in the
bladder, despite lower numbers of cir-
culating E7-CTL, a situation which is thus
different from that observed for tumors
located in the GM. A novel approach
may be to combine vaccination with
immunostimulation at the tumor location,
our recent findings suggest that this not
only increases locally the frequency of the
vaccine-specific CTL, but also leads to
a better tumor regression (unpublished
data). Altogether, our results demonstrate
the need to use animal tumor models that
closely mimic the real situation, as well
as to evaluate different immunization
routes in order to optimize immunother-
apeutic strategies against cancer located at
different mucosal sites.
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Figure 1. Vaccination routes and mucosal tumor regression.
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